VBI hepatitis B vaccine meets main goals in late-stage trial

Reuters Health Information: VBI hepatitis B vaccine meets main goals in late-stage trial

VBI hepatitis B vaccine meets main goals in late-stage trial

Last Updated: 2019-06-17

By Reuters Staff

(Reuters) - VBI Vaccines Inc said on Monday a late-stage study testing its hepatitis B vaccine against GlaxoSmithKline's Engerix-B in adults met its main goals.

The trial administered VBI's Sci-B-Vac at a 10 microgram dose against a 20 microgram dose of Engerix-B, a vaccine which was first approved in the United States in 1989.

At four weeks after the third vaccination (at day 196), the seroprotection rate (anti-HBsAg levels 10 mIU/mL) in all patients over age 18 who received Sci-B-Vac was 91.4% compared with 76.5% for those who received Engerix-B, the company said.

The seroprotection rate after three vaccinations was also higher with Sci-B-Vac in subjects age 45 and older (89.4% vs 73.1% with Engerix-B); similar advantages were also seen in diabetics and obese patients.

"We remain on track to submit applications for regulatory approvals in the U.S., Europe, and Canada beginning mid-year 2020," Chief Executive Officer Jeff Baxter said in a statement.

The company said the study did not meet a secondary goal of demonstrating two doses of Sci-B-Vac were non-inferior to three doses of Engerix-B in all patients 18 and above.

Sci-B-Vac is also being studied in another late-stage trial, whose results are expected by the year end.

© Copyright 2013-2019 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.